EMPAGLIFLOZIN SAFETY AND EFFICACY IN SOUTH INDIAN POPULATION

Abstract

Aim of this study to establish the safety and efcacy of empagliozin. It's a Longitudinal observational study conducted in Medical college on 140 Type 2 Diabetes patients. The patients who where already in other OADs and started to take Empagliozin 25mg within one week of initiation was taken into the study. The baseline value of FBS, PPBS, Weight, LDL, HDL, Sr.Electrolytes was noted. The patients will be followed up in 1st , 3rd , 6th month in each follow up visit physical examination will be done and clinical characteristic regarding adverse effects are noted. The laboratory investigations are repeated at the end of 6th month.The results are mean reduction in FBS & PPBS at the end of 6th month are 43mg/dl and 47mg/dl respectively. On observing the adverse events the incidence of hypoglycemia is 4.2%, hyponatremia is 7.5%, hypokalemia is 2.1% and Urinary tract infection is 2% . The serious adverse event is observed in one patient with a episode of DKA. There was mild increase in LDL and electrolyte imbalance. Empagliozin 25mg OD shown better efcacy with lesser side effects.